Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (418)	1/10/2005 6:08:42 PM
From: Michael Young	Respond to of 508

<<Survival is a robust and immensely important clinical endpoint>> Imagine that.

To: tuck who wrote (418)	2/7/2005 2:18:36 PM
From: vladz	Read Replies (1) \| Respond to of 508

UPDATE 2-InterMune posts loss, warns on revenue; stock off Mon Feb 7, 2005 10:49 AM ET (Recasts first paragraph, adds details on stock weakness) CHICAGO, Feb 7 (Reuters) - Biotechnology company InterMune Inc. (ITMN.O: Quote, Profile, Research) on Monday posted a deeper-than-expected quarterly loss and forecast 2005 revenue below analysts' expectations, sending its shares down nearly 10 percent. FACT BOX ITMN.O (INTERMUNE INC) Last: 10.02 Change: -1.72 Up/Down: -14.65% Quote Full Chart Company Profile Research Reports News for ITMN.O The Brisbane, California-based company said its fourth-quarter loss was $21.8 million, or 68 cents per share. Analysts' average forecast was a loss of 49 cents a share, according to Reuters Estimates. Fourth-quarter revenue fell 1 percent to $39.5 million. Sales of the drug Actimmune, designed to spur the immune system, declined 13 percent, but sales of Infergen, a drug for hepatitis C, rose 151 percent. The fourth-quarter loss narrowed from a year earlier, when InterMune lost $23.3 million, or 73 cents a share. The company forecast 2005 revenue of $140 million to $160 million. Analysts' average estimate is $163.87 million, according to Reuters Estimates. Harris Nesbitt analyst Vatnak Vat-Ho said the weaker-than-expected revenue outlook, coupled with higher projected expenses for research and development and to expand the sales force, disappointed investors. "It's mostly the revenue forecast. Also, the expense forecast was much higher than we were anticipating," he said. Shares of InterMune fell $1.15 to to $10.59 in morning trade on the Nasdaq stock market.